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Abstract
Background: Until recently, WHO recommended daily iron supplementation for all pregnant women (60 mg/d iron
combined with 400ug/d folic acid) where anaemia rates exceeded 40 %. Recent studies indicate that this may pose
a risk to pregnant women. Therefore, there is a need to explore screen-and-treat options to minimise iron exposure
during pregnancy using an overall lower dosage of iron that would achieve equivalent results as being currently
recommended by the WHO. However, there is a lack of agreement on how to best assess iron deficiency when
infections are prevalent. Here, we test the use of hepcidin a peptide hormone and key regulator of iron
metabolism, as a potential index for ‘safe and ready to receive’ iron.
Design/Methods: This is a 3-arm randomised-controlled proof-of-concept trial. We will test the hypothesis that a
screen-and-treat approach to iron supplementation using a pre-determined hepcidin cut-off value of <2.5 ng/ml
will achieve similar efficacy in preventing iron deficiency and anaemia at a lower iron dose and hence will improve
safety. A sample of 462 pregnant women in rural Gambia will be randomly assigned to receive: a)
UNU/UNICEF/WHO international multiple micronutrient preparation (UNIMMAP) containing 60 mg/d iron (reference
arm); b) UNIMMAP containing 60 mg/d iron but based on a weekly hepcidin screening indicating if iron can be
given for the next 7 days or not; c) or UNIMMAP containing 30 mg/d iron as in (b) for 12 weeks in rural Gambia.
The study will test if the screen-and-treat approach is non-inferior to the reference arm using the primary endpoint
of haemoglobin levels at a non-inferiority margin of 0.5 g/dl. Secondary outcomes of adverse effects, compliance
and the impact of iron supplementation on susceptibility to infections will also be assessed.
(Continued on next page)
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Discussion: This trial is expected to contribute towards minimising the exposure of pregnant women to iron that
may not be needed and therefore potentially harmful. If the evidence in this study shows that the overall lower
dosage of iron is non-inferior to 60 mg/day iron, this may help decrease side-effects, improve compliance and
increase safety. The potential for the use of hepcidin for a simple point-of-care (PoC) diagnostic for when it is most
safe and effective to give iron may improve maternal health outcomes.
Trial registration: ISRCTN21955180
Keywords: Pregnancy, Hepcidin, Anaemia, UNIMMAP, Lower dose iron, Iron deficiency
Background
Anaemia is a global public health problem affecting all
population groups, but especially pregnant women and
young children [1]. For pregnant women, the conse-
quences of anaemia include mortality, poor pregnancy
and birth outcomes including premature delivery, low
birth weight and increased perinatal mortality [1–3].
The most significant contributor to the onset of anaemia
is iron deficiency [1]. The World Health Organisation
(WHO) estimates that iron deficiency anaemia (IDA)
affects almost half of the world’s pregnant women and
pre-school children with a prevalence of over 65 % in
Africa and Asia, and that it causes (directly or indirectly)
one fourth of all maternal deaths [3]. In The Gambia,
iron deficiency anaemia among women and children has
been found to be high and of public health significance
with 73 % of pregnant women and 56 % of lactating
women being anaemic [4].
Although iron deficiency with or without anaemia has
important consequences for human health and child
development, there has been an absence of international
agreement on how best to assess the iron status of popu-
lations. Serum ferritin (SF) is one of the few biochemical
indices of which low levels reflect depleted iron stores
[5, 6] but it is known to be raised by infection and
inflammation as it is an acute phase protein and thus
has very high false negative rates in least developed
countries [7]. Similar problems also arise with the other
commonly used iron status indicators as summarised in
Table 1 below.
Hepcidin is a peptide hormone that has been shown
recently to be the master regulator of iron absorption
and distribution in humans [8–11]. The potential for
hepcidin as a superior marker for iron deficiency has
been highlighted in many recent studies [12–16]. Hepci-
din controls iron homeostasis by inhibiting dietary iron
absorption, release of iron in the macrophages and redu-
cing iron flow to the erythron [8, 11, 17–19]. This it
does by binding to the iron exporter ferroportin indu-
cing its internalisation and degradation [18].
Recent studies have noted that over the course of a
malaria season, hepcidin integrates signals arising from
parasitaemia, inflammation and anaemia [7, 20]. The fact
that hepcidin plays a crucial role in the above signals
and acts both as a reporter of iron status and a regulator
of iron absorption, distribution and metabolism suggests
it may be the ideal index for iron deficiency and could
form the basis of a PoC diagnostic for iron deficiency in
at-risk population groups in developing countries [20].
WHO, originally recommended universal iron supple-
mentation for all pregnant women with a dose of 60 mg
iron and 400ug folic acid daily [21]. However, a recent
study has shown that pregnant women who are anaemic
and iron deficient may be protected from malaria [22]. A
recent review also indicate that pregnant women who
received daily iron and folic acid supplementation are at
Table 1 Limitation of current methods of assessing IDA
Test Measure Limitation
Stain bone marrow preparation Iron stores Expensive, invasive and traumatic
Haemoglobin (Hb) Anaemia Does not measure ID per-se
Serum ferritin (SF) Iron stores Raised by infection and inflammation
Zinc protopopherin (ZnPP) Iron in new cells Affected by infection and inflammation
Soluble transferrin receptor (sTfR) Severe ID even
with inflammation
Affected by (>) red cell prod. Lack standardised
reference for measure’
sTfR/logSF ratio Iron stores Lack standardised assay range. Ferritin affected
by infection or inflammation
Transferrin saturation (TSAT) Iron levels Affected by (>) plasma concentration
Serum iron Iron in sera Affected by recent iron ingestion and infection
Total iron binding capacity (TIBC) Iron in serum Affected by infection
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a greater risk of haemoconcentration (haemoglobin
greater than 130 g/L) in the second and third trimester
of pregnancy [23]. Although the effect of the haemocon-
centration in the above review was uncertain, Ziaei et al.
[24] in a randomised controlled trial (RCT) of over 700
pregnant women who took 50 mg iron as ferrous
sulphate daily found that small-for-gestational-age birth
rate and the number of women with hypertensive disor-
ders increased significantly. They concluded that routine
iron supplementation in non-anaemic women is not
rational and may be harmful. Recently, two hazardous
complications of pregnancy; gestational diabetes mellitus
and preeclampsia have been recognized to be associated
with elevated body iron levels [25].
There has been little specific evidence on the relation-
ship between risk of malaria and other infections with iron
status and iron supplementation in pregnant women. Yet,
the benefits of iron supplementation must be carefully
weighed against the risks in developing countries [26, 27].
There is now some evidence that smaller doses of
30 mg iron daily could achieve similar results as the
daily 60 mg iron [21]. A Cochrane review on the treat-
ments of iron deficiency anaemia in pregnancy [28] indi-
cated that daily low dose iron supplementation may be
effective at treating anaemia in pregnancy with fewer
gastrointestinal side effects compared with higher doses.
WHO has now recommended the use of doses between
30 and 60 mg for daily supplementation for pregnant
women [29]. Further evidence suggest that the use of
multiple micronutrient supplements with three or more
micronutrients is associated with a 39 % reduction in
maternal anaemia compared with placebo or with two
micronutrients or fewer (relative risk 0 · 61, 95 % CI 0 ·
52—0 · 71). Multiple micronutrient supplementation is
also known to result in a decrease in the risk of low-
birth weight babies (0 · 83, 0 · 76—0 · 91) and small-for-
gestational-age babies (0 · 92, 0 · 86—0 · 99) [30].
In this proof of concept study we aim to test the
hypothesis that a screen-and-treat approach to iron sup-
plementation will achieve similar efficacy in combating
ID and IDA at a lower overall dosage of iron. The as-
sumption that lower doses will improve safety and toler-
ability will also be tested. The design will establish
whether using screen-and-treat with UNIMMAP con-
taining either 60 mg or 30 mg iron per day is non-
inferior to UNIMMAP containing 60 mg/day as a uni-
versal daily supplement.
Design/Methods
Study design
This study is designed as a proof-of-concept, 3-arm,
double blind, RCT over a period of 12 weeks with a
sample of 462 pregnant women randomly assigned to
receive: a) UNIMMAP containing 60 mg/day iron; b)
UNIMMAP containing 60 mg/day iron but based on a
weekly hepcidin screening indicating if iron can be given
for the next 7 days or not; c) UNIMMAP containing
30 mg/day iron based on screening as in (b).
Determining the hecidin cut-off value
The hepcidin cut-off of <2.5 ng/mL as a threshold (to
receive iron or not) is based on the analysis of sera from
270 pregnant women participating in the ENID study
[31] with samples available for 3 time points (12–14
weeks, 20 weeks and 30 weeks gestation). A receiver
operating characteristics (ROC)-curve was generated to
measure the area under the curve (AUCROC). Method
described elsewhere [12].
Study location and participants
The Hepcidin and Anaemia in Pregnancy (HAPn) study
will be carried out in 12 communities of Jarra West and
Kiang East (rural Gambia) about 150 km from the cap-
ital city of Banjul. The Regional Health Team, the health
facilities within the study area and the individual com-
munities have been sensitised and their approval gained
for conducting the study.
The study will involve 462 healthy pregnant women
between the ages of 18 and 45 years (established by ask-
ing, use of birth certificates, identity cards or calendar
events) who are pregnant (estimated at between 14 and
22 weeks gestation, by fundal height assessment and
date of last menstrual period (LMP)) and are likely to be
resident in the study area for the duration of the study
period.
Pregnant women who are identified as potential partic-
ipants will be excluded from the study if found to be (i)
severely anaemic (<7 g/dL), (ii) seriously ill (infectious
disease of clinical significance) at recruitment (iii) suffer
from a chronic disease (iv) have pregnancy complica-
tions (e.g., pre-eclampsia) at enrolment or (v) already
participating in another study.
Detailed study procedure
Screening and enrollment (Baseline)
Pregnant women living within the two health facility
catchment areas will be identified as they visit the
Reproductive and Child Health (RCH) clinics to register
and book their pregnancies. As part of the routine
services provided, a nurse midwife determines their
stage of pregnancy. If a woman is within the window of
the study (14–22 weeks gestation), she will be invited by
the study team to take part in the study and informed
consent will be sought. Once a signed informed consent
is obtained and all of the inclusion and none of the
exclusion criteria are met, she will be enrolled in the
study, and asked to provide 5 mL venous blood (Day 0
below). Participants will thereafter be assigned to one of
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the 3 study groups (see randomisation, below). All
women enrolled in to the study will be provided with
long lasting insecticide-treated bed nets (LLINs).
Follow-up
Following recruitment, women will be followed up
weekly in their communities. Each week, trained MRC
field assistants (FA) will invite the study participants to a
central location within their communities for collection
of a finger prick blood sample for analysis of haemoglo-
bin (Hb) using a HemoCue Hb 301 analyser (Hemo-
CueAB, Angelholm, Sweden), malaria parasitaemia using
a SD Bioline One step malaria antigen Pf Test (SD
Standard Diagnostics, Inc. Kyonggi-do, Korea) and hep-
cidin levels using the BACHEM Hepcidin-25 ELISA. Hb
and malaria assessments will be performed immediately;
samples for hepcidin measurements will be transferred
on ice to a laboratory at MRC Keneba where analysis
will commence within the hour of arrival. The following
day hepcidin results will be available and a 7 day supply
of supplements packed according to the hepcidin results
(computer generated). The day after, participants will be
provided with their supplements. While the supplements
are being distributed, the FA will also assess beneficial
effects, adverse events and compliance. All activities will
be documented on a case report form (CRF) using elec-
tronic data capture in the form of a hand held device
(SAMSUNG Galaxy Tab3 Model SM-T211). Data will be
sent through a secure internet connection to the MRC
database.
Ethics and safety monitoring
The trial has been approved by the Medical Research
Council (MRC) Scientific Coordinating Committee (SCC)
and the Joint Gambia Government MRC Ethics Commit-
tee. It will be overseen by a Data Safety Monitoring Board
(DSMB) and a Trial Steering Committee assisted by a
Trial Monitor (TM). Together they will be responsible for
reviewing all interim data, treatment safety and efficacy
including the protection of the rights and wellbeing of the
participants. The trial will be conducted according to
Good Clinical Practice (GCP) principles taking in to con-
sideration the provisions of the World Medical Associ-
ation (WMA) Declaration of Helsinki (October 2013).
Participants will be monitored on each scheduled follow
up day for all adverse events (AEs) defined as any unto-
ward or unfavourable medical occurrence in a human sub-
ject, including signs and symptoms which are temporally
associated with the research procedure or trial interven-
tion, whether or not considered related to the subject’s
participation in the research. All serious adverse events
(SAEs) defined as any AE that is life-threatening or results
in death or require hospitalisation or prolongation of
hospitalisation, is a persistent or significant disability/
incapacity or is a congenital anomaly/birth defect or a
reported maternal death, miscarriage or stillbirth will be
recorded as SAEs and investigated by a physician. Moni-
toring of the participants will then continue until they
deliver and the outcome of the pregnancy for both mother
and child is known (postnatal check-up within 72 h after
delivery).
Collection and analyses of biological samples
during enrollment and follow-up visits
As described, finger prick blood samples will be collected
weekly. Additional 5 mL venous blood samples will also be
collected at 4 different time-points (Days 0, 14, 49 and 84)
within the 12 week period of the study. As intermittent
preventative treatment (IPT) is routine in this region, par-
ticipants will receive their IPT dose immediately after
blood draws are done at days 14 and 49 in order not to in-
fluence our ex vivo P. falciparum assays. All venous blood
draws will be carried out by the study nurse and finger
prick blood samples by the field assistants (FAs).
Full haematology including haemoglobin and reticulo-
cytes will be assessed on samples collected on Days 0,
14, 49 and 84 in a 1.2 mL EDTA Sarstedt tube using the
Medonic M Series analyser.
Biochemistry analysis of plasma ferritin, iron, transfer-
rin saturation (TSAT), soluble transferrin receptor
(sTfR), C-reactive protein (CRP), and alpha-1-acid glyco-
protein (AGP) will be measured by Cobas Integra 400+
using 500 μl from −20 frozen samples. The Cobas meas-
uring principle for ferritin, transferrin and CRP will be
via turbidimetric principle at 552 nm, 340 nm and
552 nm respectively and for iron, FerroZine method
without deproteinization. sTfR will be measured photo-
metrically at 583 nm and alpha-1-acid glycoprotein will
be through turbidimetric. Hb genotyping will be per-
formed using Hb electrophoresis with Shandon Vokam
400 on all samples collected on Day 0.
This study is not powered to use clinical endpoints to
assess safety. Instead the trial will use in vitro assays to
assess safety on each of the four venous samples per
subject. Ex vivo growth of P. falciparum will be assessed
in washed red blood cells (RBCs) using a field-ready 96-
well plate method with florescence-activated cell sorting
(FACS) readout [32]. A small subset of RBCs will be lysed
for measurement of riboflavin status by the erythrocyte
glutathione reductase activation coefficient (EGRAC) test
because this may affect RBC stability.
The ex vivo growth of sentinel organisms (Escheri-
chia coli, Yersinia enterocolitica, S. enterica serovar
(Typhimurium), Staphylococcus epidermidis, Staphylo-
coccus aureus and Candida albicans) analyses will be
performed in frozen (−20 °C) plasma (400 μl) as previ-
ously described in the investigation of the effects of
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iron supplementation on pathogen virulence in human
serum [33].
DNA will be extracted from baseline whole blood sam-
ples to study the genes implicated in iron metabolism.
Known genetic risk factors for malaria assays will include
alpha-thalassemia, G6PD and sickle traits. Furthermore,
putative functional and key tagging variants in iron regula-
tory and inflammatory pathways will be screened.
Randomisation and blinding
Randomisation
Recruited women will be randomly assigned (computer
generated) to one of the 3 treatment arms (equal num-
ber in each arm) balanced by the Hb concentration of
the baseline blood sample and gestational age. To
achieve this, at each day of recruitment, subjects will be
categorised into two Hb classes (above and below the
median Hb of the respective day) and according to 2
gestational age periods (14–18 weeks, 19–22 weeks)
making 4 classes. In each of the 4 classes, the women
will be randomly assigned to the 3 treatment arms using
a predetermined block randomisation.
The randomisation database of treatment arms (A, B, C)
will be password protected with the database developer
and his assistant knowing the password. If a subject needs
to be unblinded at the request of the DSMB, their treat-
ment can be easily identified without unblinding the whole
study.
Blinding
Participants, field workers, study nurse and PI will be
blinded as to which treatment group participants belong
to and which supplement participants receive each week.
The supplements will be pre-packed on a weekly basis
by the field coordinator in Keneba using lists automatic-
ally (computer) generated by the data office taking into
account the hepcidin results of the participants. The list
will indicate the letter of the supplement the participant
receives for the following 7 days but the field coordin-
ator will not know which code is allocated to which sup-
plement. The capsules are coded (2 codes for treatment
arm A (60 mg and 60 mg iron), 2 codes for arm B
(60 mg and 0 mg iron) and 2 codes for arm C (30 mg
and 0 mg iron), see Fig. 1. The pre-packed weekly sup-
plies labelled with each participant’s ID will be handed
over to the PI who will be responsible for handing them
over to the field workers who will distribute to the indi-
vidual participants. The laboratory staff and data entry
clerks will also be blinded.
The allocation of the colour code will be done by 2
people independent of the study and the key will be kept
in a locked cabinet in Keneba. The blinding for the study
may be broken if in any of the 3 treatment arms, safety
issues arise and the trial team is advised by the DSMB to
do so.
Investigational product
The investigational product to be used is the UNICEF/
WHO/UNU international multiple micronutrient prep-
aration (UNIMMAP). Three products will be adminis-
tered (UNIMMAP with 60 mg iron, UNIMMAP with
30 mg iron, UNIMMAP with 0 mg iron). All formula-
tions also contain 400 ug folic acid and 14 other micro-
nutrients (Table 2). The UNIMMAP supplement has
already been used safely in other pregnancy trials [34].
The formulations are produced by DSM South Africa
under Good Manufacturing Practice (GMP) conditions
where it will also be dosed into gelatin capsules and packed
in tubs. The labelling will include a statement that ‘trial
medications are only for use of trial participant’.
The products will be stored under controlled condi-
tions (in an air-conditioned storage at around 20 °C) at
MRC Keneba. The product is stable for 18 months if
kept under these conditions.
Each participant will receive 1 capsule per day. Each
week field workers will be visiting study participants to
distribute the respective weekly supply (7 capsules) to
each study participant. The participants will be instructed
to take 1 capsule a day with water or another drink. Each
time the field workers distribute the new weekly supply of
capsules they will account for the number of capsules
consumed/not consumed from the previous week in order
to check for compliance. Any left-over capsules will be
collected by the field workers.
Sample size and statistical analysis plan
Sample size determination
Using the haemoglobin data obtained from pregnant
women enrolled in the ENID study in West Kiang [31],
a SD of 1.28 was derived. This was used to obtain a sam-
ple size of 154 participants for each of the 3 arms
Fig. 1 An example of blinding using colour codes
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(Table 3) calculated using a 1-sided α (alpha) of 2.5 with
a conservative-Bonferroni type correction (÷3) so as not
to inflate the type 1 error rates while performing mul-
tiple tests. A total sample size of 462 pregnant women
followed up for 12 weeks with a less than 10 % loss to
follow-up will provide 80 % power to establish that:
1) arm B is non-inferior to arm A on the primary end-
point defined below.
2) arm C is non-inferior to arm A at the same level as
described in the statistical analysis plan.
3) arm C is non-inferior to arm B.
Note: it is being stated a priori that arm C will be
compared with B for non-inferiority to explore if the re-
sults can influence policy on the further lowering of the
dose of iron for those not iron deficient. The study
(sample size) is powered for this analysis.
Statistical analysis plan
The approach to the analysis for this trial will be a test of
non-inferiority. As recommended for the acceptance of
non-inferiority analysis, a per-protocol (PP) analysis will
be performed. Additional analysis including all Hb mea-
surements (not only day 84) will be explored. These will
be described in a more detail statistical analysis plan.
Primary endpoint
The primary non-inferiority endpoint is pregnancy-
adjusted haemoglobin at Day 84. To adjust for multiple
testing (3 arms), non-inferiority will be tested with a
96.7 % CI of the lower 0.83 % (2.5 %/3) limit for the
difference. The lower confidence limit for the differ-
ence in haemoglobin concentration between the uni-
versal and screened treatments on Day 84 will be
above −0.5 g/dL ( −5 g/L), the smallest value consid-
ered to be of minimum public health relevance. See
illustration in Fig. 2.
Secondary endpoints
i. Proportion of Hb < 11 g/dL (%) at Day 84.
ii. Hepcidin at Day 84 (as a continuous variable but
also using a cut-off point of >2.5 ng/mL to calculate
the proportion).
iii. sTfR/log-ferritin ratio (ferritin index <2.0) at Day 84
(continuous variable but a proportion will also be
calculated).
iv. Iron deficiency anaemia (IDA) defined as Hb < 11 g/
dL and ferritin < 15 ug/L when CRP is < 5 mg/L OR
Hb < 11 g/dL and ferritin < 30 ug/L when CRP is >
5 mg/L and ferritin index < 2.0.
v. Iron dosage (number of weeks supplemented).
vi. Adverse events that may include nausea/vomiting,
dizziness, constipation, black stool, stomach
discomfort assessed weekly will be evaluated at Day
28 and Day 84. In addition, an aggregate score will
also be assessed.
vii.Compliance.
viii.P. falciparum growth in serum (difference between
in vitro growth rates at Days 0, 14, 49 and 84).
ix. Ex vivo growth of sentinel bacteria (difference
between in vitro growth rates at Days 0, 14, 49 and 84).
Analysis of the continuous variables (ii) and (iii) will
be based on comparing means using a t-distribution
where 95 % CI is calculated for the difference in arm A
compared to B and C respectively and also between B
and C. A logarithmic transformation will be applied to
non-normally distributed variables and unpaired t-tests
done on the transformed data. For variables (i), (iv), (v),
(vi), (vii), (viii) and (ix), a frequency distribution using X2
comparing proportions between the arms will be per-
formed with a statistical test for significance for the
difference between the arms set at 5 % (P < 0.05). Add-
itionally, adverse events will be analysed using multiple
Table 2 Intervention product - Formulation based on UNU/
UNICEF/WHO supplement called UNIMMAP
Micronutrients Dose/day
Vitamin A (ug RE) 800
Vitamin D (IU) 200
Vitamin E (mg) 10
Thiamine (mg) 1.4
Riboflavin (mg) 1.4
Niacin (mg) 18
Folic acid (ug) 400
Vitamin B6 (mg) 1.9
Vitamin B12 (ug) 2.6
Vitamin C (mg) 70
Zinc (mg) 15
Iron (mg) 60 or 30 or 0
(placebo)
Iodine (ug) 150
Selenium (ug) 65
Copper (mg) 2
Table 3 Study arms
Group Dose (mg/day Fe) Universal (N) Screen with Hepcidin
(Yes or No)
A 60 154 No
Ba 60 154 Yes
Ca 30 154 Yes
aGroups B and C will be tested weekly and only given their next seven day
supply of iron if plasma hepcidin falls below cut-off for ‘safe and ready’
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regression analysis controlling for possible confounders
to see which events or aggregate score are associated to
which arm. Compliance will be assessed comparing pro-
portions consumed in each arm with number consumed
as numerator and the total number of capsules prescribed
between enrolment and end of study as the denominator.
STATA 12.1 or any of its latest versions will be used for all
the analyses.
Further exploratory analysis will be conducted and the
endpoints include:
Primary endpoints adjusted for CRP, AGP and malaria
(we decided a priori that the primary endpoints will not
be adjusted for the above, however, we wish as part of an
exploratory analysis to adjust for them), sTfR, Ferritin, and
TSAT.
Informed consent and confidentiality
All field workers taking part in the recruitment of partic-
ipants will be trained on translating and issuing of the
informed consent documentation. The information sheet
will be translated to all the illiterate participants in a lan-
guage that they understand in the presence of an inde-
pendent witness. The literate participants will be allowed
to read the information sheet in their own time. Partici-
pants will also be encouraged to ask questions and seek
clarification from the field workers and the PI. If the par-
ticipant agrees to take part in the study, informed con-
sent is recorded by a signature or thumbprint.
Participants will be allocated an individual identifica-
tion number. Participant identification numbers will be
used on all samples and data forms generated during the
course of the study. Following sample collection and
data entry, linkage of the ID back to the study partici-
pant will not be possible without a lookup table, which
will be held by the data manager only and his designated
data staff during the course of the study. The field
worker will have a printout version of the list. Once data
collection is complete, analysis will be performed on an
anonymised copy of the data. All forms and case report
forms (CRF) will be kept in locked files. At all stages,
staff/collaborators responsible for sample analysis will be
blinded as to the subject’s identification. Together, these
processes will ensure complete confidentiality of the data
gathered and impartiality of data analyses.
Discussion
WHO has identified the need for a lower dose in iron
supplementation as recommendations being used by
countries can pose risks to some pregnant women. This
trial will test the efficacy of employing a screen-and-
treat approach to minimise iron exposure whilst achiev-
ing a similar therapeutic effect.
As 50 % of anaemia in pregnancy is assumed to be due
to ID, the assessment of iron status (not only anaemia)
in supplementation programmes is critical and hepcidin
has shown the potential of being an improved bio-
marker for iron status and therefore a signal for the safe
administration of iron in pregnancy. In this study we will
explore this potential of hepcidin with a pre-determined
cut-off value of <2.5 ng/ml to screen for the readiness to
receive iron. When iron is needed, we will supplement
using oral, tablet form UNIMMAP formulation contain-
ing 60 mg iron daily (universal) on one hand or provide
60 or 30 mg iron daily only when hepcidin levels are
below the threshold cut-off value mentioned above (screen-
and-treat). We hypothesise that a screen-and-treat ap-
proach to iron supplementation will achieve similar efficacy
in combating ID and IDA at a lower overall dosage of iron
as therapy will be targeted to periods when the enterocyte
iron absorption channels are open. We assume that lower
doses will improve safety and tolerability and these will be
tested as secondary outcomes.
In summary, this trial will contribute towards minimis-
ing exposure to excessive iron that may not be needed
and may indeed be harmful and allow the pregnant
woman to maximise the absorption and utilisation of
iron when it is most needed. In addition, the overall
lower dosage may help decrease side-effects and increase
compliance. The exploration of hepcidin as a potential
for a simple PoC diagnostic to screen for the readiness
Fig. 2 Confidence interval approach to analysis of non-inferiority trial
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to receive iron will assist health workers to make the
right decisions for iron supplementation which will help
in improving health care delivery and reduce maternal
morbidity and mortality as part of efforts to meet the
Millennium Development Goal 5 and the forthcoming
Sustainable Health Agenda.
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